



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox NX-1207 Successful Clinical Trial Results Featured in *Urology Times*

NX-1207 Treatment for BPH In Phase 3 Development

HASBROUCK HEIGHTS, NJ (December 19, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that recent successful clinical trial results for NX-1207, the Company's new drug for benign prostatic hyperplasia (BPH) is featured in the *Urology Times*, the widely distributed and most read publication of U.S. urologists. The *Urology Times* article entitled "Investigational benign prostatic hyperplasia drug improves urgency, frequency" refers to the 47% reduction in symptoms of urgency and 43% improvement in the frequency of urination, both of which were largely maintained for one year after a single treatment with NX-1207.

In addition, news of the NX-1207 clinical studies success has been shown on many U.S. television networks.

NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort. Patients notice improvement as early as a week or two after treatment. Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for 2 years or more. NX-1207 treatment does not require the patient to take pills daily for the rest of his life, like currently approved BPH medications.

Presentations of clinical study data at urology meetings have been well-received and the Company has received a large number of communications from patients and doctors throughout the U.S. and internationally, interested in participating in clinical trials. Investigative site recruitment activities are proceeding well.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###